334 related articles for article (PubMed ID: 22807134)
1. Assessment of the potential pathogenicity of missense mutations identified in the GTPase-activating protein (GAP)-related domain of the neurofibromatosis type-1 (NF1) gene.
Thomas L; Richards M; Mort M; Dunlop E; Cooper DN; Upadhyaya M
Hum Mutat; 2012 Dec; 33(12):1687-96. PubMed ID: 22807134
[TBL] [Abstract][Full Text] [Related]
2. Interaction between a Domain of the Negative Regulator of the Ras-ERK Pathway, SPRED1 Protein, and the GTPase-activating Protein-related Domain of Neurofibromin Is Implicated in Legius Syndrome and Neurofibromatosis Type 1.
Hirata Y; Brems H; Suzuki M; Kanamori M; Okada M; Morita R; Llano-Rivas I; Ose T; Messiaen L; Legius E; Yoshimura A
J Biol Chem; 2016 Feb; 291(7):3124-34. PubMed ID: 26635368
[TBL] [Abstract][Full Text] [Related]
3. Characterization of Ras effector mutant interactions with the NF1-GAP related domain.
Marshall MS; Hettich LA
Oncogene; 1993 Feb; 8(2):425-31. PubMed ID: 8426748
[TBL] [Abstract][Full Text] [Related]
4. A novel neurofibromin (NF1) interaction with the leucine-rich pentatricopeptide repeat motif-containing protein links neurofibromatosis type 1 and the French Canadian variant of Leigh's syndrome in a common molecular complex.
Arun V; Wiley JC; Kaur H; Kaplan DR; Guha A
J Neurosci Res; 2013 Apr; 91(4):494-505. PubMed ID: 23361976
[TBL] [Abstract][Full Text] [Related]
5. Noonan syndrome and neurofibromatosis type I in a family with a novel mutation in NF1.
Nyström AM; Ekvall S; Allanson J; Edeby C; Elinder M; Holmström G; Bondeson ML; Annerén G
Clin Genet; 2009 Dec; 76(6):524-34. PubMed ID: 19845691
[TBL] [Abstract][Full Text] [Related]
6. Exhaustive non-synonymous variants functionality prediction enables high resolution characterization of the neurofibromin architecture.
Isakov O; Wallis D; Evans DG; Ben-Shachar S
EBioMedicine; 2018 Oct; 36():508-516. PubMed ID: 30274822
[TBL] [Abstract][Full Text] [Related]
7. Mutational and functional analysis of the neurofibromatosis type 1 (NF1) gene.
Upadhyaya M; Osborn MJ; Maynard J; Kim MR; Tamanoi F; Cooper DN
Hum Genet; 1997 Jan; 99(1):88-92. PubMed ID: 9003501
[TBL] [Abstract][Full Text] [Related]
8. Farnesyltransferase inhibitors block the neurofibromatosis type I (NF1) malignant phenotype.
Yan N; Ricca C; Fletcher J; Glover T; Seizinger BR; Manne V
Cancer Res; 1995 Aug; 55(16):3569-75. PubMed ID: 7627966
[TBL] [Abstract][Full Text] [Related]
9. Reconstitution of the NF1 GAP-related domain in NF1-deficient human Schwann cells.
Thomas SL; Deadwyler GD; Tang J; Stubbs EB; Muir D; Hiatt KK; Clapp DW; De Vries GH
Biochem Biophys Res Commun; 2006 Sep; 348(3):971-80. PubMed ID: 16908010
[TBL] [Abstract][Full Text] [Related]
10. Differential expression of two types of the neurofibromatosis type 1 (NF1) gene transcripts related to neuronal differentiation.
Nishi T; Lee PS; Oka K; Levin VA; Tanase S; Morino Y; Saya H
Oncogene; 1991 Sep; 6(9):1555-9. PubMed ID: 1923522
[TBL] [Abstract][Full Text] [Related]
11. Structural and biochemical consequences of NF1 associated nontruncating mutations in the Sec14-PH module of neurofibromin.
Welti S; Kühn S; D'Angelo I; Brügger B; Kaufmann D; Scheffzek K
Hum Mutat; 2011 Feb; 32(2):191-7. PubMed ID: 21089070
[TBL] [Abstract][Full Text] [Related]
12. Dynamic regulation of the Ras pathway via proteolysis of the NF1 tumor suppressor.
Cichowski K; Santiago S; Jardim M; Johnson BW; Jacks T
Genes Dev; 2003 Feb; 17(4):449-54. PubMed ID: 12600938
[TBL] [Abstract][Full Text] [Related]
13. Analysis of mutations and expression of GAP-related domain of the neurofibromatosis type 1 (NF1) gene in the progression of chronic myelogenous leukemia.
Nakai H; Misawa S; Horiike S; Taniwaki M; Seriu T; Shimazaki C; Fujii H; Maekawa T; Furukawa T; Abe T
Leukemia; 1994 Jun; 8(6):1027-33. PubMed ID: 8207976
[TBL] [Abstract][Full Text] [Related]
14. Selective disactivation of neurofibromin GAP activity in neurofibromatosis type 1.
Klose A; Ahmadian MR; Schuelke M; Scheffzek K; Hoffmeyer S; Gewies A; Schmitz F; Kaufmann D; Peters H; Wittinghofer A; Nürnberg P
Hum Mol Genet; 1998 Aug; 7(8):1261-8. PubMed ID: 9668168
[TBL] [Abstract][Full Text] [Related]
15. Neurofibromatosis type I tumor suppressor neurofibromin regulates neuronal differentiation via its GTPase-activating protein function toward Ras.
Yunoue S; Tokuo H; Fukunaga K; Feng L; Ozawa T; Nishi T; Kikuchi A; Hattori S; Kuratsu J; Saya H; Araki N
J Biol Chem; 2003 Jul; 278(29):26958-69. PubMed ID: 12730209
[TBL] [Abstract][Full Text] [Related]
16. NF1 regulates a Ras-dependent vascular smooth muscle proliferative injury response.
Xu J; Ismat FA; Wang T; Yang J; Epstein JA
Circulation; 2007 Nov; 116(19):2148-56. PubMed ID: 17967772
[TBL] [Abstract][Full Text] [Related]
17. Antisense therapeutics for neurofibromatosis type 1 caused by deep intronic mutations.
Pros E; Fernández-Rodríguez J; Canet B; Benito L; Sánchez A; Benavides A; Ramos FJ; López-Ariztegui MA; Capellá G; Blanco I; Serra E; Lázaro C
Hum Mutat; 2009 Mar; 30(3):454-62. PubMed ID: 19241459
[TBL] [Abstract][Full Text] [Related]
18. NF1 modulates the effects of Ras oncogenes: evidence of other NF1 function besides its GAP activity.
Corral T; Jiménez M; Hernández-Muñoz I; Pérez de Castro I; Pellicer A
J Cell Physiol; 2003 Nov; 197(2):214-24. PubMed ID: 14502561
[TBL] [Abstract][Full Text] [Related]
19. Neurofibromin in neurofibromatosis type 1 - mutations in NF1gene as a cause of disease.
Abramowicz A; Gos M
Dev Period Med; 2014; 18(3):297-306. PubMed ID: 25182393
[TBL] [Abstract][Full Text] [Related]
20. Pathogenic Mutations Associated with Legius Syndrome Modify the Spred1 Surface and Are Involved in Direct Binding to the Ras Inactivator Neurofibromin.
Führer S; Tollinger M; Dunzendorfer-Matt T
J Mol Biol; 2019 Sep; 431(19):3889-3899. PubMed ID: 31401120
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
